Market Newsdesk

BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the AMPA-associated protein, TARP8 have been updated to the correct term, TARPγ8. The omission was due to a conversion issue when the release was formatted for distribution. The revised release follows:

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical expression of TARPγ8 was confirmed

In the MAD-2 trial, RAP-219 was observed to be generally well tolerated with faster titration and higher exposures than in the initial MAD trial

Data underscore the potential broad therapeutic index of RAP-219 and dosing flexibility

Ongoing Phase 2a trial of RAP-219 in focal epilepsy is on track and topline data is expected in mid-2025

Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced results from its positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial for RAP-219. Data from the trials demonstrated that RAP-219 achieved target receptor occupancy (RO) associated with maximal efficacy in prior preclinical models within five days of dosing while maintaining a differentiated tolerability profile.

“These Phase 1 results reinforce our belief in RAP-219’s distinct profile and potential to deliver transformative outcomes for patients,” said Steve Paul, M.D., Rapport cofounder and chair of the board of directors. “The data demonstrate that neuroanatomical specificity can be achieved through RAP-219’s selective targeting of a receptor-associated protein, and RAP-219 was able to quickly achieve target engagement and therapeutic exposures in the brain while maintaining a generally favorable tolerability profile. Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy.”

A total of four Phase 1 trials have been conducted to date, with 100 healthy volunteers exposed to RAP-219. In these trials, RAP-219 was generally well tolerated in multiple repeat-dose studies with up to 28 days of dosing, with no serious adverse events (SAEs), no treatment emergent adverse events (TEAEs) greater than Grade 2, and no clinically relevant laboratory or electrocardiogram (ECG) abnormalities. Three treatment discontinuations occurred (3%) that were attributed to TEAEs. The trials also showed that favorable tolerability was achieved with various dosing and titration regimens. Rapport believes the pharmacokinetic (PK) and tolerability outcomes from these clinical trials provide compelling translational evidence of selectively targeting TARPγ8 associated AMPA receptors to significantly enhance the therapeutic index of AMPA receptor modulation.

“Due to the non-specific nature of currently available and other investigational treatments, many patients continue to endure significant side effects, which limit therapeutic efficacy and diminish their quality of life,” said Abe Ceesay, chief executive officer of Rapport. “RAP-219 was designed to overcome such limitations, and we believe these compelling new data support our approach as we advance our Phase 2a trial in focal epilepsy, with topline results expected in mid-2025.”

Also announced today, Bradley Galer, M.D., has stepped down as chief medical officer of Rapport. A search for his successor is underway, and the Company is confident that the transition will not disrupt progress across its clinical programs.  Dr. Galer will be assisting the transition, and the Company is grateful for his support and contributions to Rapport over the past two years.

Results from the recent PET and MAD-2 trials are below, based on preliminary analysis of the data. Clinical conduct of the PET and MAD-2 trials is complete, and the clinical study reports for both are in progress.

The PET trial (RAP-219-103) was an open label trial in healthy volunteers designed to confirm neuroanatomical expression of TARPγ8 and establish the relationship between PK and brain target RO with RAP-219. The trial included three cohorts: Cohort 1 was given the same dosing regimen currently being used in the Phase 2a trial in focal epilepsy (0.75 mg daily for 5 days, followed by 1.25 mg daily for 9 days), and lower doses were used in the other two cohorts to better characterize the plasma concentration versus RO relationship. Cohort 2 was given 0.25 mg daily for 14 days and Cohort 3 was given 0.25 mg daily for 7 days, followed by 0.5 mg daily for 7 days.

PET trial results are summarized below:

• The PET data demonstrated that Cohort 1 (the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy) exceeded the target RO range associated with maximal efficacy in prior preclinical models (50%-70%) within five days of dosing, while maintaining a differentiated tolerability profile generally consistent with prior Phase 1 trial findings.
• The trial confirmed that the expression of TARPγ8-containing AMPA receptors is enriched in the hippocampus and cerebral cortex and is minimal in the cerebellum and brain stem.
• Collectively, data from the PET and MAD-2 trials demonstrated that plasma concentrations and associated target RO could be achieved within 5 days.

The MAD-2 (RAP-219-104) trial was a double-blind, placebo-controlled trial in healthy volunteers and was the second MAD trial of RAP-219. The trial was designed to further evaluate safety and tolerability with continued dose escalation, as well as to shorten time to reach predicted therapeutic levels of RAP-219. The trial included three cohorts: Cohort 1 (0.75 mg for 3 days, 1.25 mg for 3 days, 1.75 mg for 2 days), Cohort 2 (0.75 mg for 2 days, 1.25 mg for 2 days, 1.75 mg for 4 days), and Cohort 3 (0.5 mg for 2 days, 1 mg for 2 days, 1.75 mg for 24 days).

MAD-2 trial results are summarized below:

• RAP-219 was generally well tolerated. All TEAEs were Grade 1 or 2 and generally consistent with tolerability observed in prior Phase 1 trials.
• Unlike with many anti-seizure medications, no sedation or motoric impairments were observed with RAP-219, consistent with target biology and preclinical observations.
• Target exposures and RO were achieved within 5 days of dosing across various dosing regimens.

A Phase 2a proof-of-concept trial is currently underway to evaluate RAP-219 in patients with refractory focal epilepsy, with topline results expected in mid-2025.

About RAP-219

RAP-219 is a clinical-stage AMPA receptor negative allosteric modulator designed to achieve neuroanatomical specificity through its selective targeting of AMPA-associated protein, TARPγ8. AMPA receptors are present throughout the brain, including in the cerebellum and brain stem, where their non-selective targeting has resulted in poor tolerability. In contrast, TARPγ8 expression is enriched in the hippocampus and cerebral cortex and is minimal in the cerebellum and brain stem. RAP-219 is designed to be highly potent and selective for TARPγ8. It has been observed to have a long half-life (8–14 days) and minimal drug-drug interactions, making it potentially well-suited for polypharmacy. With this profile, RAP-219 has the potential to provide improved activity, tolerability, and a higher therapeutic index, potentially providing more patients with sustained therapeutic benefits without intolerable side effects, as compared to traditional neuroscience medications. As AMPA receptors play critical roles in numerous neurological disorders, selective targeting of TARPγ8 may provide a pipeline-in-a-product opportunity. The Company is currently pursuing RAP-219 as a potentially differentiated treatment for patients with focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania.

About Rapport Therapeutics

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients suffering from central nervous system (CNS) disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.

Forward-Looking Statements

This press release contains​ “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the broad therapeutic index of RAP-219 and its ability to deliver transformative outcomes for patients; the clinical development of RAP-219 for the treatment of drug-resistant focal epilepsy, peripheral neuropathic pain and bipolar acute mania, including expected dosing flexibility; the expected timing of the results from ongoing clinical trials; the activity and tolerability of RAP-219, including its neuroanatomical specificity; and Rapport’s RAP technology platform.

Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Rapport’s business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the company’s research and development activities, including that interim, topline and preliminary data from our clinical trials that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data; Rapport’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Rapport’s ability to attract, integrate and retain key personnel; risks related to the company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport’s intellectual property protections; and risks related to the competitive landscape for Rapport’s product candidates; as well as other risks described in​ “Risk Factors,” in the company’s Registration Statement on Form S-1, and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport’s subsequent filings with the Securities and Exchange Commission. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company’s first-ever SPD product with distinguishable black appearance
can be seen on display at Gauzy’s Booth #6516 in Automotive West Hall

Enables Gauzy to further solidify its already dominant position in SPD Smart Glass, a market expected to reach $13.4 billion in value by the end of 2031

World’s most powerful tech event provides Gauzy the opportunity to showcase several additional light and vision control products, including introducing its transformative Solar-Powered energy harvesting Light Control Glass (LCG

^®

) for the first time in the U.S.

NEW YORK and TEL AVIV, Israel, Jan. 09, 2025 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ), a global leader in light and vision control technology, is pleased to announce that it has unveiled its latest suspended particle device (SPD) Smart Glass technology at CES 2025, the most influential tech event in the world. Gauzy’s first-ever black SPD Smart Glass technology has a distinguishable black appearance and was created to accommodate the robust demand from the three strong and growing markets that the company targets – the automotive, aeronautics, and architecture industries – for a dark and neutral colored dimmable glass that enhances design while supporting visual and thermal comfort. This new product has been developed to continue offering the same appreciated performance of the existing SPD products sold by Gauzy and currently adopted in the market, while offering the neutral black color the market has requested. Gauzy expects the black SPD product to be available for commercial orders and serial production in the future.

This latest innovation positions Gauzy to further solidify its already dominant market share within the smart glass industry. The popularity of SPD Smart Glass – as well as polymer dispersed liquid crystal (PDLC) Smart Glass, which the company also develops and manufactures – continues to rise due to its numerous advantages over traditional shading systems and other smart glass solutions, including its ability to transition from clear to fully opaque within seconds, block more than 99% of visible light, reduce energy consumption, regulate temperature control, increase headroom in vehicles by at least two inches, extend driving ranges in electric vehicles, and its ability to be retrofitted to existing structures, vehicles, aircraft, among other strategic benefits. As a result, the SPD Smart Glass market is expected to grow at a compound annual growth rate of 9.9% from 2024-2031, reaching $13.4 billion in value by the end of 2031.

“Over the last few quarters, many of our high-profile customers across the automotive, aeronautics, and architecture sectors have expressed their desire for SPD Smart Glass with a black appearance, and we are thrilled to unveil it at CES 2025,” stated Eyal Peso, CEO of Gauzy. “Our ability to work expeditiously to innovate and create a solution that the market demands reflects the sophistication of our research and development capabilities and exemplifies why we continue to grow and solidify our competitive position in light control. We believe this new offering and its darker aesthetics will broaden the number of users who implement Smart Glass into their designs going forward, and we anticipate that it will quickly become one of our top-selling SPD products.”

The new black SPD Smart Glass technology by Gauzy will be on display throughout the duration of CES at Gauzy’s Booth #6516 in the Automotive West Hall. Gauzy invites all CES attendees to stop by and experience the many features of SPD technology and discover why a growing number of world-renowned OEMs like Ferrari, McLaren, Mercedes, and Cadillac have chosen to incorporate SPD into their automotive designs in serial production.

Joseph M. Harary, President and CEO of Research Frontiers (Nasdaq: REFR), commented from CES: “SPD is the best performing instantly switchable smart glass solution for shading and has become extremely popular with its existing color for sky facing applications such as sunroofs and skylights. As our market penetration expands to vertically-oriented glass on the side of cars and buildings, this new development being shown today with a more neutral color is impactful. This new capability to offer a black SPD-Smart Glass product, along with Gauzy’s Solar Powered smart glass innovation and the recent announcement of the retrofit application for our smart glass, will make it easier and more cost effective to install smart windows in homes, apartments and office buildings.”

Gauzy is also showcasing several other of its groundbreaking solutions at its booth at the world’s most powerful tech event, including introducing its newly-announced Solar Powered LCG^® for the first time in the U.S. This transformative technology redefines the capabilities of smart glass. By embedding Gauzy’s LCG^® PDLC and SPD technologies with transparent solar cells, Gauzy enables smart glass to harvest energy from the sun. This integration of solar cells with Gauzy’s light control technologies allows the panels to generate and harvest electricity that can be used to power electrical devices within a vehicle or building, including the smart glass system itself, providing an alternative source of energy that can contribute to reduced operating costs and increased sustainability and energy efficiency initiatives across industries.

Moreover, additional light and vision control products of Gauzy’s that increase safety, comfort and sustainability are on display in the company’s booth, including smart glass sunroofs, side door windows and sun visors with either SPD or PDLC technology, its AI-powered advanced driver assistance system (ADAS) Smart-Vision^® for buses and trucks; a 55″ LG Display T-OLED with segmented SPD and smart glass and shading solutions for commercial and private aircraft as well as railway.

About Gauzy

Gauzy Ltd. is a fully-integrated light and vision control company, focused on the research, development, manufacturing, and marketing of vision and light control technologies that are developed to support safe, sustainable, comfortable, and agile user experiences across various industries. Headquartered in Tel Aviv, Israel, the company has additional subsidiaries and entities based in Germany, France, the United States, Canada, China, Singapore, and the United Arab Emirates. Gauzy serves leading brands across aeronautics, automotive, and architecture in over 30 countries through direct fulfillment and a certified and trained distribution channel.

About Research Frontiers

Research Frontiers (Nasdaq: REFR) is a publicly traded technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to numerous companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, please visit our website at www.SmartGlass.com, and on Facebook, Twitter, LinkedIn and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gauzy’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements reflect Gauzy’s current views, plans, or expectations with respect to future events and financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Gauzy’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict including, without limitation, the following: Gauzy invests significant effort and capital seeking validation of its light and vision control products with OEMs and Tier 1 suppliers, mainly in the aeronautics and automobile markets, and there can be no assurance that it will win production models, which could adversely affect its future business, results of operations and financial condition; failure to make competitive technological advances will put Gauzy at a disadvantage and may lead to a negative operational and financial outcome; Gauzy being an early growth-stage company with a history of losses and its anticipation that it expects to continue to incur significant losses for the foreseeable future; its operating results and financial condition have fluctuated in the past and may fluctuate in the future; it is exposed to high repair and replacement costs; it may not be able to accurately estimate the future supply and demand for its light and vision control products, which could result in a variety of inefficiencies in its business and hinder its ability to generate revenue; if it fails to accurately predict its manufacturing requirements, it could incur additional costs or experience delays; the estimates and forecasts of market opportunity and market growth it provides may prove to be inaccurate, and it cannot assure that its business will grow at similar rates, or at all; it may be unable to adequately control the capital expenditures and costs associated with its business and operations; it may need to raise additional capital before it can expect to become profitable from sales of its light and vision control products, which such additional capital may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force it to delay, limit or terminate its product development efforts or other operations; shortages in supply, price increases or deviations in the quality of the raw materials used to manufacture its products could adversely affect its sales and operating results; its business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by the ongoing conflict between Russia and Ukraine; it is subject to, and must remain in compliance with, numerous laws and governmental regulations across various countries concerning the manufacturing, use, distribution and sale of its light and vision control products, and some of its customers also require that it complies with other unique requirements relating to these matters; if it is unable to obtain, maintain and protect effective intellectual property rights for its products throughout the world, it may not be able to compete effectively in the markets in which it operates; the market price of its ordinary shares may be volatile or may decline steeply or suddenly regardless of its operating performance, and it may not be able to meet investor or analyst expectations; its indebtedness could adversely affect its ability to raise additional capital to fund operations, limit its ability to react to changes in the economy or its industry and prevent it from meeting its financial obligations; it has limited operating experience as a publicly traded company in the United States; conditions in Israel could materially and adversely affect its business; and any other risks and uncertainties, including, but not limited to, the risks and uncertainties in the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company’s prospectus (Registration No. 333-278675), dated June 5, 2024 and filed with the SEC. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Gauzy or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Gauzy undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

IR and Media Contact Info

Media:
Brittany Kleiman Swisa
Gauzy Ltd.
[email protected]

Investors:
Dan Scott, ICR Inc.
[email protected]

AE50 2025: Ten Ag innovations from CNH awarded by ASABE

Basildon, January 9, 2024

Customer-inspired Ag Tech and Engineering solutions from CNH’s Case IH and New Holland brands have won ten AE50 2025 awards. These awards honor the year’s 50 most innovative products and systems engineered for the food and agricultural industries. Winners are determined by the American Society of Agricultural and Biological Engineers (ASABE).

Our Winners

Case IH

The Axial-Flow (AF) 260 series combines bring together the latest innovations with subscription-free, integrated technology. The combine sets a new standard for operator experience while also maximizing production and grain handling with single-rotor Case IH harvesting technology.

The AF combine series has been redesigned from the ground up to maximize capacity and crop flow with efficient horsepower, simplified maintenance and connectivity as standard.

The C500 series corn heads were created to seamlessly pair with the AF and 260 series combines, delivering reliability, durability and enhanced grain savings and performance.

Large Square Baler Automation controls are designed for hands-free efficient baling, automatically adjusting tractor speed and steering to match windrow volume to maximize throughput for consistent, high-quality bales.

The Quadtrac Heavy-Duty Suspension brings greater productivity by facilitating faster transport speeds of up to 26.5 mph with a smoother ride thanks to the fully suspended track system, which closely follows ground contours.

Model Year 2025 Magnum tractors with 21×5 PowerDrive transmissions will benefit from Automatic Productivity Management 2 (APM2). APM2 technology manages the driveline and engine to control ground speed while optimizing fuel economy and prevents engine stalls.

The Modular Tramline System for the Early Riser 2160 48-row 20-inch Large Front-Fold planter offers industry-leading 20-inch planter tramline compatibility, productivity, and performance. The Modular Tramline System is tailored to the swath sizes of a farmer’s equipment fleet while minimizing the number of unused tramlines – areas of the field which are not planted and over which the vehicles drive – bringing increased yield potential, productivity and reduced operator fatigue.

New Holland

The IntelliSense™ Bale Automation system uses cutting-edge technology that integrates SmartSteer™ swath guidance to keep the baler in the middle of the windrow, together with IntelliCruise II™ speed control which uses LiDAR (light detection and ranging) technology to adjust the balers forward speed in real-time. This ensures the baler is always full for more efficient baling and higher quality bales.

The CropSpeed Monitoring System, featured in the FR Forage Cruiser range of self-propelled forage harvesters, increases productivity using radar technology to detect the speed of crop, and if it detects a potential spout blockage, the operator receives a warning to reduce forward speed.

The UltraFeed™ Pickup head is also designed to enhance the performance of the FR Forage Cruiser. Its 13-foot working width means the UltraFeed Pickup efficiently handles larger windrows, and thanks to a range of new features, improves crop flow through the harvester.

CNH’s continued inclusion in prestigious awards, such as the AE50 – where this year we received 20% of all awards – reaffirms our commitment to advancing innovation through our iconic brands, delivering solutions that make farming more efficient, effective, and sustainable.

CNH Industrial

(NYSE: CNH) is a world-class equipment, technology and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally,

Case IH

and

New Holland

supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and

CASE

and

New Holland Construction Equipment

deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include:

STEYR

, for agricultural tractors;

Raven

, a leader in digital agriculture, precision technology and the development of autonomous systems;

Hemisphere

, a leading designer and manufacturer of high-precision satellite-based positioning, and heading technologies;

Flexi-Coil

, specializing in tillage and seeding systems;

Miller

, manufacturing application equipment; and

Eurocomach,

producing a wide range of
mini and midi excavators for the construction sector, including electric solutions. 

Across a history spanning over two centuries, CNH has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH’s 40,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.  

For more information and the latest financial and sustainability reports visit:


cnh.com

 

For news from CNH and its Brands visit:


media.cnh.com

 

Media contacts:

[email protected]

Attachments

• 20250109_PR_CNH_AE50 Awards
• Case IH AF11 Combine Header
• Case IH Modular_Tramline_System_For_Case_IH_Early_Riser_2160_48_Row_20-inch_Large_Front-Fold_Planter
• Case IH Steiger_715_and_Ecolo-Tiger_875_0411_10-22 (1)
• New Holland IntelliSense BigBaler
• New Holland FR CropSpeed Monitoring System
• New Holland FR UltraFeed™ Pickup

 VANCOUVER, Wash., Jan. 09, 2025 (GLOBE NEWSWIRE) — Riverview Bancorp, Inc. (Nasdaq GSM: RVSB) is pleased to announce that Charmaine Lightheart has been named EVP/Chief Retail and Digital Engagement Officer for Riverview Bank. Charmaine has spent nearly 20 years at all levels of banking, where she has served as a branch manager and leader of treasury management working her way to Regional Manager, Senior Vice President, and Director roles. Charmaine has built her career at First Independent Bank, Sterling Bank, Heritage Bank and most recently, two years at Riverview Bank as Senior Vice President, Director of Retail Services.

“We are thrilled to name Charmaine to Executive Vice President, recognizing her exceptional leadership and commitment to fostering innovation in retail banking and client services. Her vision and dedication to employees and clients are paramount in deepening relationships and making a meaningful difference in the communities we serve,” said Nicole Sherman, CEO/President of Riverview Bank.

Outside of her professional career, Charmaine is committed to her community. She is actively involved in her children’s school within the Camas School District. She has served on various community steering committees and boards. Charmaine currently serves on the Board of Directors for NW Furniture Bank, contributing her strategic insight to drive organizational growth and direction.

Charmaine holds a Master of Business Administration Management and is a graduate of the Pacific Coast Banking School. Her leadership, commitment to building strong teams, and dedication to both professional and community success make her a respected figure in the banking industry.

“I am thrilled to embark on my new role as EVP/Chief Retail and Digital Engagement Officer at Riverview Bank, where I have the incredible opportunity to contribute to strengthening our vibrant community. With a passion for serving both employees and clients, I am committed to helping them thrive and achieve success. It’s a privilege to be part of a community -focused bank that is deeply committed to fostering growth and success for everyone it serves,” said Charmaine Lightheart.

Charmaine lives in Camas, Washington with her husband and two daughters. You can find the Lightheart family enjoying many aspects of their community and on the quest for the perfect pizza.

About the Company

Riverview Bancorp, Inc. (www.riverviewbank.com) is headquartered in Vancouver, Washington – just north of Portland, Oregon, on the I-5 corridor. With assets of $1.55 billion on September 30, 2024, it is the parent company of Riverview Bank, as well as Riverview Trust Company. The Bank offers true community banking services, focusing on providing the highest-quality service and financial products to commercial, business, and retail clients through 17 branches, including 13 in the Portland-Vancouver area, and 3 lending centers. For the past 11 years, Riverview has been named Best Bank by the readers of The Columbian.

This press release contains statements that the Company believes are “forward-looking statements.” These statements relate to the Company’s financial condition, results of operations, plans, objectives, future performance or business. You should not place undue reliance on these statements, as they are subject to risks and uncertainties. When considering these forward-looking statements, you should keep in mind these risks and uncertainties, as well as any cautionary statements the Company may make. Moreover, you should treat these statements as speaking only as of the date they are made and based only on information then actually known to the Company.

ADDISON, Texas, Jan. 09, 2025 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today announced the closing of its acquisition of Profire Energy, Inc., as of January 3, 2025, (formerly NASDAQ: PFIE) (“Profire”), a technology company and industry-leading provider of intelligent control solutions that enhance the efficiency, safety, and reliability of industrial combustion appliances while mitigating potential environmental impacts related to the operation of these devices with its primary operations in Lindon, Utah and Acheson, Alberta.

As previously announced, CECO, Combustion Merger Sub and PFIE entered into an Agreement and Plan of Merger on October 28, 2024, pursuant to which CECO commenced a cash tender offer to acquire all of the issued and outstanding shares of PFIE common stock at a price of $2.55 per share, in cash, without interest, and subject to applicable withholding tax. Also as previously disclosed, the tender offer expired at one minute after 11:59 P.M., New York City time, on December 31, 2024, after which time CECO accepted for payment and paid for all shares validly tendered.

On January 3, 2025, following the expiration of the tender offer and acceptance for payment of the shares validly tendered and not validly withdrawn pursuant to the tender offer and the satisfaction of the remaining conditions to the merger, the Company completed its acquisition of PFIE. As a result of the completion of the transaction, PFIE’s common stock is no longer listed on any public market. The aggregate consideration paid by CECO to acquire the shares of PFIE was approximately $122.7M, which CECO financed through a combination of cash on hand and borrowings under its existing credit facility.
“I am excited to welcome the Profire team to CECO as we advance our strategic portfolio of leading environmental solution businesses in niche energy and industrial markets,” said Todd Gleason, CECO’s Chief Executive Officer. “Together, I believe that we will accelerate Profire’s growth by accelerating expansion in new energy, industrial and international markets.”

ABOUT CECO ENVIRONMENTAL

CECO Environmental is a leading environmentally focused, diversified industrial company, serving a broad landscape of industrial air, industrial water, and energy transition markets globally through its key business segments: Engineered Systems and Industrial Process Solutions. Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean, and more efficient solutions that help protect people, the environment and industrial equipment. In regions around the world, CECO works to improve air quality, optimize the energy value chain, and provide custom solutions for applications in power generation, petrochemical processing, refining, midstream gas transport and treatment, electric vehicle and battery production, metals and mineral processing, polysilicon production, battery recycling, beverage can production, and produced and oily water/wastewater treatment along with a wide range of other industrial applications. CECO is listed on Nasdaq under the ticker symbol “CECO.” Incorporated in 1966, CECO’s global headquarters is in Dallas, Texas. For more information, please visit www.cecoenviro.com.

SAFE HARBOR STATEMENT

Any statements contained in this Press Release, other than statements of historical fact, including statements about management’s beliefs and expectations, are forward-looking statements and should be evaluated as such. These statements are made on the basis of management’s views and assumptions regarding future events and business performance and include, but are not limited to, statements about CECO’s expectations regarding the integration of PFIE into CECO; the benefits of the acquisition of PFIE and the expectations regarding the transaction’s impact on CECO’s strategic growth plan. We use words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “will,” “plan,” “feel,” “should” and similar expressions to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Potential risks and uncertainties that could cause actual results to differ materially include risks regarding the effect of the transaction on business relationships, operating results, and business generally, disruption of current plans and operations and potential difficulties in employee retention as a result of the transaction, diversion of management’s attention from ongoing business operations in connection with the integration of the transaction, the outcome of any legal proceedings that have been or may in the future be instituted related to the transaction, the amount of the costs, fees, expenses and other charges related to the transaction, the achievement of the anticipated benefits of the transaction, the ability of PFIE to achieve its earnings guidance, our ability to successfully integrate acquired businesses and realize the synergies from acquisitions, as well as a number of factors related to our business, including the sensitivity of our business to economic and financial market conditions generally and economic conditions in our service areas; dependence on fixed price contracts and the risks associated therewith, including actual costs exceeding estimates and method of accounting for revenue; the effect of growth on our infrastructure, resources, and existing sales; the ability to expand operations in both new and existing markets; the potential for contract delay or cancellation as a result of on-going or worsening supply chain challenges; liabilities arising from faulty services or products that could result in significant professional or product liability, warranty, or other claims; changes in or developments with respect to any litigation or investigation; failure to meet timely completion or performance standards that could result in higher cost and reduced profits or, in some cases, losses on projects; the potential for fluctuations in prices for manufactured components and raw materials, including as a result of tariffs and surcharges, and rising energy costs; inflationary pressures relating to rising raw material costs and the cost of labor; the substantial amount of debt incurred in connection with our strategic transactions and our ability to repay or refinance it or incur additional debt in the future; the impact of federal, state or local government regulations; our ability to repurchase shares of our common stock and the amounts and timing of repurchases, if any; our ability to successfully realize the expected benefits of our restructuring program; our ability to successfully integrate acquired businesses and realize the synergies from strategic transactions; the unpredictability and severity of catastrophic events, including cyber security threats, acts of terrorism or outbreak of war or hostilities or public health crises, as well as management’s response to any of the aforementioned factors; and our ability to remediate our material weakness, or any other material weakness that we may identify in the future that could result in material misstatements in our financial statements. Additional risks and uncertainties are discussed under “Part I – Item 1A. Risk Factors” of CECO’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and may be included in subsequently filed Quarterly Reports on Form 10-Q. Many of these risks are beyond management’s ability to control or predict. Should one or more of these risks or uncertainties materialize, or should the assumptions prove incorrect, actual results may vary in material aspects from those currently anticipated. Investors are cautioned not to place undue reliance on such forward-looking statements as they speak only to our views as of the date the statement is made. Except as required under the federal securities laws or the rules and regulations of the Securities and Exchange Commission, we undertake no obligation to update or review any forward-looking statements, whether as a result of new information, future events or otherwise.

CECO Company Contact:

Peter Johansson
Chief Financial and Strategy Officer
888-990-6670
796-5127

Investor Relations Contact:

Steven Hooser
Three Part Advisors
214-872-2710
[email protected]

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) — Warner Music Group Corp. will release its financial results on Thursday, February 6, 2025, for the first quarter ended December 31, 2024, and will hold an earnings conference call that morning at 8:30 a.m. ET.

To access the conference call, please register here. Once registered, you will receive an email with the dial-in number along with your personalized pin needed to join the call. We suggest you call in 10 minutes prior to the start time. If you do not anticipate asking a question, we recommend joining via the webcast at www.wmg.com. The replay of the conference call will also be available via the webcast at www.wmg.com.

About Warner Music Group

Warner Music Group (WMG) brings together artists, songwriters, entrepreneurs, and technology that are moving entertainment culture across the globe. Operating in more than 70 countries through a network of affiliates and licensees, WMG’s Recorded Music division includes renowned labels such as 10K Projects, 300 Entertainment, Asylum, Atlantic, Big Beat, EastWest, Elektra, Erato, First Night, Fueled By Ramen, Nonesuch, Parlophone, Reprise, Rhino, Roadrunner, Sire, Spinnin’, Warner Records, Warner Classics, and Warner Music Nashville. WMG’s music publishing arm, Warner Chappell Music, has a catalog of over one million copyrights spanning every musical genre, from the standards of the Great American Songbook to the biggest hits of the 21st century. Warner Music Group is also home to ADA, which supports the independent community, as well as artist services division WMX. Follow WMG on Instagram, X, TikTok, LinkedIn, and Facebook.

Investor Relations Contact:

Kareem Chin
[email protected]  

Media Contact:

James Steven
[email protected]